A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis

OBJECTIVES: Recent advances in systemic sclerosis (SSc) show that it involves a T-helper type-2-oriented immune response with interleukin (IL)-4 and IL-13. Romilkimab is an engineered, humanised, bispecific immunoglobulin-G4 antibody that binds and neutralises IL-4/IL-13 making it ideal for explorat...

Descripción completa

Detalles Bibliográficos
Autores principales: Allanore, Yannick, Wung, Peter, Soubrane, Christina, Esperet, Corinne, Marrache, Frederic, Bejuit, Raphael, Lahmar, Amel, Khanna, Dinesh, Denton, Christopher P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Systemic Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677494/
https://www.ncbi.nlm.nih.gov/pubmed/32963047
http://dx.doi.org/10.1136/annrheumdis-2020-218447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677494/
https://www.ncbi.nlm.nih.gov/pubmed/32963047
http://dx.doi.org/10.1136/annrheumdis-2020-218447

Ejemplares similares